Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.

Koehn BH, Saha A, McDonald-Hyman C, Loschi M, Thangavelu G, Ma L, Zaiken M, Dysthe J, Krepps W, Panthera J, Hippen K, Jameson SC, Miller JS, Cooper MA, Farady CJ, Iwawaki T, Ting JP, Serody JS, Murphy WJ, Hill GR, Murray PJ, Bronte V, Munn DH, Zeiser R, Blazar BR.

Blood. 2019 Nov 7;134(19):1670-1682. doi: 10.1182/blood.2019001950.

PMID:
31533918
2.

Differential Regulation of T-cell Immunity and Tolerance by Stromal Laminin Expressed in the Lymph Node.

Simon T, Li L, Wagner C, Zhang T, Saxena V, Brinkman CC, Tostanoski LH, Ostrand-Rosenberg S, Jewell C, Shea-Donohue T, Hippen K, Blazar B, Abdi R, Bromberg JS.

Transplantation. 2019 Oct;103(10):2075-2089. doi: 10.1097/TP.0000000000002774.

PMID:
31343575
3.

Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets.

Tanimine N, Germana SK, Fan M, Hippen K, Blazar BR, Markmann JF, Turka LA, Priyadharshini B.

PLoS One. 2019 Jun 6;14(6):e0217761. doi: 10.1371/journal.pone.0217761. eCollection 2019.

4.

CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration.

Xiong Y, Piao W, Brinkman CC, Li L, Kulinski JM, Olivera A, Cartier A, Hla T, Hippen KL, Blazar BR, Schwab SR, Bromberg JS.

Sci Immunol. 2019 Mar 15;4(33). pii: eaav1263. doi: 10.1126/sciimmunol.aav1263.

5.

Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.

Yang J, Ramadan A, Reichenbach DK, Loschi M, Zhang J, Griesenauer B, Liu H, Hippen KL, Blazar BR, Paczesny S.

JCI Insight. 2019 Mar 7;4(5). pii: 122014. doi: 10.1172/jci.insight.122014. eCollection 2019 Mar 7.

6.

The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation.

Liu B, Salgado OC, Singh S, Hippen KL, Maynard JC, Burlingame AL, Ball LE, Blazar BR, Farrar MA, Hogquist KA, Ruan HB.

Nat Commun. 2019 Jan 21;10(1):354. doi: 10.1038/s41467-019-08300-3.

7.

Induction of immunosuppressive functions and NF-κB by FLIP in monocytes.

Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Bicciato S, Blazar BR, Sahin U, Murray PJ, Bronte V.

Nat Commun. 2018 Dec 5;9(1):5193. doi: 10.1038/s41467-018-07654-4.

8.

The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease.

McDonald-Hyman C, Muller JT, Loschi M, Thangavelu G, Saha A, Kumari S, Reichenbach DK, Smith MJ, Zhang G, Koehn BH, Lin J, Mitchell JS, Fife BT, Panoskaltsis-Mortari A, Feser CJ, Kirchmeier AK, Osborn MJ, Hippen KL, Kelekar A, Serody JS, Turka LA, Munn DH, Chi H, Neubert TA, Dustin ML, Blazar BR.

J Clin Invest. 2018 Oct 1;128(10):4604-4621. doi: 10.1172/JCI95713. Epub 2018 Aug 14.

9.

The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells.

Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, Walsh DA, Block KE, Fonseca R, Yan Y, Hippen KL, Blazar BR, Masopust D, Kelekar A, Vulchanova L, Hogquist KA, Jameson SC.

Nature. 2018 Jul;559(7713):264-268. doi: 10.1038/s41586-018-0282-0. Epub 2018 Jul 4.

10.

Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, Cichocki F, Blazar BR, Miller JS.

Cancer Immunol Res. 2018 Jul;6(7):766-775. doi: 10.1158/2326-6066.CIR-17-0498. Epub 2018 May 21.

11.

miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg).

Lu Y, Gao J, Zhang S, Gu J, Lu H, Xia Y, Zhu Q, Qian X, Zhang F, Zhang C, Shen H, Hippen KL, Blazar BR, Lu L, Wang X.

Cell Death Dis. 2018 Feb 19;9(3):290. doi: 10.1038/s41419-018-0298-2.

12.

Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease.

Hippen KL, Loschi M, Nicholls J, MacDonald KPA, Blazar BR.

Front Immunol. 2018 Jan 31;9:57. doi: 10.3389/fimmu.2018.00057. eCollection 2018. Review.

13.

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.

Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Gołab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grześ D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P.

Front Immunol. 2018 Jan 15;8:1844. doi: 10.3389/fimmu.2017.01844. eCollection 2017.

14.

Human in vitro-induced regulatory T cells display Dlgh1dependent and PKC-θ restrained suppressive activity.

Zanin-Zhorov A, Kumari S, Hippen KL, Merkel SC, MacMillan ML, Blazar BR, Dustin ML.

Sci Rep. 2017 Jun 26;7(1):4258. doi: 10.1038/s41598-017-04053-5.

15.

A robust in vitro model for trans-lymphatic endothelial migration.

Xiong Y, Brinkman CC, Famulski KS, Mongodin EF, Lord CJ, Hippen KL, Blazar BR, Bromberg JS.

Sci Rep. 2017 May 9;7(1):1633. doi: 10.1038/s41598-017-01575-w.

16.

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

Hippen KL, O'Connor RS, Lemire AM, Saha A, Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, June CH, Turka LA, Kean LS, MacMillan ML, Miller JS, Wagner JE, Munn DH, Blazar BR.

Am J Transplant. 2017 Dec;17(12):3098-3113. doi: 10.1111/ajt.14338. Epub 2017 Jun 14.

17.

Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

McKenna DH Jr, Sumstad D, Kadidlo DM, Batdorf B, Lord CJ, Merkel SC, Koellner CM, Curtsinger JM, June CH, Riley JL, Levine BL, Miller JS, Brunstein CG, Wagner JE, Blazar BR, Hippen KL.

Cytotherapy. 2017 Feb;19(2):250-262. doi: 10.1016/j.jcyt.2016.10.011. Epub 2016 Nov 22.

18.

Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.

Hippen KL, Watkins B, Tkachev V, Lemire AM, Lehnen C, Riddle MJ, Singh K, Panoskaltsis-Mortari A, Vanhove B, Tolar J, Kean LS, Blazar BR.

Transplantation. 2016 Dec;100(12):2630-2639. doi: 10.1097/TP.0000000000001465.

19.

Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota.

Khoruts A, Hippen KL, Lemire AM, Holtan SG, Knights D, Young JH.

Transl Res. 2017 Jan;179:116-125. doi: 10.1016/j.trsl.2016.07.013. Epub 2016 Jul 25. Review.

20.

miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.

Lu Y, Hippen KL, Lemire AL, Gu J, Wang W, Ni X, Ranganathan P, Levine BL, Riley JL, June CH, Turka LA, Munn DH, Garzon R, Lu L, Blazar BR.

Blood. 2016 Sep 8;128(10):1424-35. doi: 10.1182/blood-2016-05-714535. Epub 2016 Aug 2.

Supplemental Content

Loading ...
Support Center